Table 1A.
Cohort overview and response to DLI.
| All | Relapse | Continuous Remission | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N | 13 | 8 | 5 | ||||||||
| Age at DLI, y | 57 (22–75) | 51 (24–61) | 67 (22-75) | ||||||||
| Sex, male | 6 (46) | 4 (50) | 2 (40) | ||||||||
| Disease Details, sAML | 2 (15) | 1 (13) | 1 (20) | ||||||||
| Disease risk, adverse risk* | 4 (31) | 3 (38) | 1 (20) | ||||||||
| Donor age at alloHSCT, y | 33 (24-58) | 36 (28-43) | 30 (24-58) | ||||||||
| Donor sex, male | 9 (69) | 5 (63) | 4 (80) | ||||||||
| Conditioning regimen, RIC | 6 (46) | 3 (38) | 3 (60) | ||||||||
| aGVHD post alloHSCT | 4 (31) | 3 (38) | 1 (20) | ||||||||
| cGVHD post alloHSCT | 6 (46) | 3(38) | 3 (60) | ||||||||
| DLI Trigger: relapse -Hematological relapse -Molecular relapse |
13 (100) -11 (85) -2 (15) |
8 (100) -7 (88) -1 (13) |
5 (100) -4 (80) -1 (20) |
||||||||
| Antineoplastic treatment pre DLI | 13 (100) | 8 (100) | 5 (100) | ||||||||
| Response to antineoplastic treatment pre DLI* | |||||||||||
| -CRi, iHC -PR -SD |
-4 (31) -7 (54) -2 (15) |
-1 (20) -5 (63) -2 (40) |
-3 (60) -2 (40) -0 (0) |
||||||||
| First DLI, mo post alloHSCT | 13 (3-47) | 12 (3-47) | 24 (6-28) | ||||||||
| Dose first DLI, CD3+/kg BW | 1×107 (1,5×106-1×107) | 1×107 (1,6×106-1×107) | 1×107 (1,5×106-1×107) | ||||||||
| Total number of DLI | 2 (1-3) | 2 (1-3) | 2 (2) | ||||||||
| Cumulative amount of applied donor cells (CD3+/kg BW) | 1.6x107 (1.6x106-6.5x107) | 4.55x107 (1.6x106-6.5x107) | 1.3x107 (1.5x107-6x107) | ||||||||
| Antineoplastic treatment post DLI | 11 (85) | 8 (100) | 3 (60) | ||||||||
| First GVL, mo post DLI | 2 (1-3) | 2 (1-3) | 2 (2-3) | ||||||||
| aGVHD post DLI | 5 (38) | 3 (38) | 2 (40) | ||||||||
| cGVHD post DLI | 7 (54) | 4 (50) | 3 (60) | ||||||||
| Severe cGVHD post DLI | 3 (23) | 2 (25) | 1 (20) | ||||||||
| Overlap GVHD post DLI | 5 (38) | 3 (38) | 2 (40) | ||||||||
| Relapse, mo post DLI | 4 (1-20) | 4 (1-20) | – | ||||||||
| OS at 24 mo post DLI, mo | 22 (2-24) | 11 (2-24) | 24 (10-24) | ||||||||
| Patients alive at 24 mo post DLI | 6 (46) | 2 (25) | 4 (80) | ||||||||
Given is the median (range) for continuous variables and the absolute number (%) for categorical variables. aGVHD, acute graft-versus-host disease; alloHSCT, allogeneic hematopoietic stem cell transplantation; BW, bodyweight; cGVHD, chronic graft-versus-host disease; CRi, complete remission with incomplete hematological recovery; CTx, chemotherapy; DLI, donor lymphocyte infusion; GVL, graft-versus-leukemia effect; iHC, increased host chimerism; mo, months; OS, overall survival; PR, partial remission; SD, stable disease; RIC, reduced intensity conditioning; sAML, secondary acute myeloid leukemia; y, years. *according to ELN response criteria (35).